These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 32564750)

  • 21. [Dynamics of staphylococcus aureus antibiotic resistance to fluoroquinolones in vitro in patients with overweight].
    Dukhovich TV; Chopei IV; Chubirko KI
    Wiad Lek; 2018; 71(2 pt 1):301-305. PubMed ID: 29729160
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibacterial activity of a DNA topoisomerase I inhibitor versus fluoroquinolones in Streptococcus pneumoniae.
    Valenzuela MV; Domenech M; Mateos-Martínez P; González-Camacho F; de la Campa AG; García MT
    PLoS One; 2020; 15(11):e0241780. PubMed ID: 33141832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expanded activity and utility of the new fluoroquinolones: a review.
    Blondeau JM
    Clin Ther; 1999 Jan; 21(1):3-40; discussion 1-2. PubMed ID: 10090423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The newer fluoroquinolones.
    Bolon MK
    Infect Dis Clin North Am; 2009 Dec; 23(4):1027-51, x. PubMed ID: 19909896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Moxifloxacin: new preparation. A me-too with more cardiac risks.
    Prescrire Int; 2002 Dec; 11(62):168-9. PubMed ID: 12469694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative in-vitro efficacy of fluoroquinolones against Streptococcus pneumoniae recovered from bacterial keratitis as determined by E-test.
    Ramakrishnan R; Ramesh S; Bharathi MJ; Amuthan M; Viswanathan S
    Indian J Pathol Microbiol; 2010; 53(2):276-80. PubMed ID: 20551532
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
    Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
    Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Mohamed NM; Zakaria AS; Edward EA; Abdel-Bary A
    Pol J Microbiol; 2019; 68(1):59-69. PubMed ID: 31050254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Ciprofloxacin and antibacterial therapy of respiratory tract infections].
    Ivanov DV; Budanov SV
    Antibiot Khimioter; 2006; 51(5):29-37. PubMed ID: 17310788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone.
    Nilius AM; Shen LL; Hensey-Rudloff D; Almer LS; Beyer JM; Balli DJ; Cai Y; Flamm RK
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3260-9. PubMed ID: 14506039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluoroquinolone antibacterials: a review on chemistry, microbiology and therapeutic prospects.
    Sharma PC; Jain A; Jain S
    Acta Pol Pharm; 2009; 66(6):587-604. PubMed ID: 20050522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outpatient fluoroquinolone prescribing patterns before and after US FDA boxed warning.
    Bratsman A; Mathias K; Laubscher R; Grigoryan L; Rose S
    Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):701-707. PubMed ID: 32390266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility.
    Cattoir V; Nectoux J; Lascols C; Deforges L; Delchier JC; Megraud F; Soussy CJ; Cambau E
    Int J Antimicrob Agents; 2007 Apr; 29(4):389-96. PubMed ID: 17303392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibiotic therapy for acute uncomplicated pyelonephritis in women. Take resistance into account.
    Prescrire Int; 2014 Dec; 23(155):296-300. PubMed ID: 25629148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of Salmonella spp. with resistance to extended-spectrum cephalosporins and fluoroquinolones isolated in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).
    Biedenbach DJ; Toleman M; Walsh TR; Jones RN
    Diagn Microbiol Infect Dis; 2006 Jan; 54(1):13-21. PubMed ID: 16290025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pharmacodynamic and pharmacokinetic evaluation of respiratory fluoroquinolones. Guideline to selection of the most appropriate fluoroquinolone].
    Parra-Ruiz J; Hernández-Quero J
    Rev Esp Quimioter; 2012 Dec; 25(4):245-51. PubMed ID: 23303254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin.
    Kocsis B; Domokos J; Szabo D
    Ann Clin Microbiol Antimicrob; 2016 May; 15(1):34. PubMed ID: 27215369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of fluoroquinolone-resistant beta-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone-resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobial Surveillance Program (1997-2004).
    Biedenbach DJ; Toleman MA; Walsh TR; Jones RN
    Diagn Microbiol Infect Dis; 2006 Jun; 55(2):119-27. PubMed ID: 16530373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates.
    Morgan-Linnell SK; Becnel Boyd L; Steffen D; Zechiedrich L
    Antimicrob Agents Chemother; 2009 Jan; 53(1):235-41. PubMed ID: 18838592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preserving the efficacy of front-line fluoroquinolones through selective use to optimise clinical outcomes.
    Lode HM
    Int J Antimicrob Agents; 2014 Jun; 43(6):497-507. PubMed ID: 24787481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.